Hybridon is the leader in the development of oligonucleotide chemistries for therapeutics and diagnostics. Its primary technology platforms are:
· Antisense: Advanced chemistry antisense oligonucleotides to elucidate gene function and as drug candidates to treat disease
· Immunomodulatory Oligonucleotides: a portfolio of proprietary CpG-like synthetic DNA (Hybridon’s IMOs) for use alone or with other agents to modulate immune responses
· Cycliconä: Hybridon’s antisense discovery tool for analysis of gene expression and PCR-based gene amplification.
Hybridon plans to create value through a combination of in-house development of products, collaboration with partners, and the licensing of broadly applicable technology.
Board of Directors
James B. Wyngaarden, M.D. Chairman, Hybridon, Inc. Romer Director, National Institute of Heath
Youssef El Zein Vice Chairman, Hybridon, Inc. Chief Executive Officer, Pillar, S.A.
Sudhir Agrawal, D. Phil. President and Chief Scientific Officer Hybridon, Inc.
Arthur W. Berry Former Chairman and Managing Director, Pecks Management Partners Ltd.
Camille Chebeir President, Sedco Services, Inc.
Keith Hartley Managing Partner, Hartley Capital Advisors, Merchant Bankers
Nassar Menhall Chief Executive Officer, WorldCare, Ltd
Paul C. Zamecnik, M.D. Professor of Medicine Emeritus, Harvard Medical School Honorary Physician and Senior Scientist, The Massachusetts General Hospital
Senior Management
Sudhir Agrawal, D. Phil. President, Chief Scientific Officer
R. Russell Martin, M.D. Senior Vice President of Drug Development
Robert G. Andersen Vice President of Operations and Planning and Chief Financial Officer
Jinyan Tang, Ph.D. Vice President of Chemistry
John M. Naples Controller
Contact Information
Address:
Hybridon, Inc.
345 Vassar Street
Cambridge, MA 02139
Phone: 617-679-5500
Fax: 617-679-5592
IR Contact:
R. Russell Martin, M.D.
Sr. Vice President
617-679-5593
rmartin@hybridon.com
Transfer Agent
ChaseMellon Shareholder Services, L.L.C.
Overpeck Centre
85 Challenger Road
Ridgefield Park, NJ 07660
800-288-9541
www.chasemellon.com
While you are being so helpful, how about posting the shareholders for a couple different years?
Therein lies the goods!
Checking out the fronts and the dots, and the twisted mazes,compared to the clean sounding names like General Motors and National Institutes of Health makes for fun!
People may be fooled by the first glance,but researching builds the indictments!